dium channels found in sensory nerve endings that can increase in chronic painful conditions, and is in Phase II clinical development for a variety of pain-related disorders. In 2011, the company formed a consumer health care joint venture with P&G, combining its OTC pharmaceutical businesses in all markets outside North America. The company manufactures products to supply the joint venture’s markets, as well as P&G’s existing North American OTC business. The company owns 49% of the joint venture, and P&G owns 51%. As of December 2012, the OTC products of Cephalon (Mepha) were included in the joint venture. Dispositions In January 2013, the company sold its U.S.-based animal health business, exiting the business. Significant Events In March 2014, OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. History Teva Pharmaceutical Industries Limited was founded in 1901.
teva pharmaceutical-sp adr
5 Basel Street
Petach Tikva, 49131
Phone: 972 3 926 7267
Fax: 972 3 923 4050www.tevapharm.com
|AbbVie Inc||$67.71 USD||-0.21|
|Actavis plc||$265.39 USD||+1.64|
|Baxter International Inc||$74.48 USD||+0.41|
|Eli Lilly & Co||$72.40 USD||-0.05|
|Valeant Pharmaceuticals International Inc||C$165.46 CAD||-0.32|
|View Industry Companies|
Sponsored Financial Commentaries
To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.